House Eyes Bill to Allow Drug Expenditures to Count Toward Insurance Deductibles

Why It Matters

Ensuring all drug spend counts toward deductibles could reduce financial barriers, accelerate adoption of lower‑cost direct‑to‑patient channels, and pressure insurers and manufacturers to compete on price.

Key Takeaways

• Direct-to-patient drug purchases often bypass deductible credit
• Current plans require channel‑specific purchases for deductible counting
• The Every Dollar Counts Act would credit all drug spend
• Bill aims to reduce patient “double‑pay” and improve access
• Expected to boost competition among pharmacy platforms

Pulse Analysis

The rise of direct‑to‑patient (DTP) pharmacy platforms has introduced a new pricing dynamic, offering patients lower out‑of‑pocket costs for high‑priced brand medications. However, most health insurers still tie deductible credit to purchases made through traditional, plan‑designated channels. This mismatch forces patients to split their spending between DTP services and conventional pharmacies, effectively paying twice for the same therapeutic benefit and delaying care.

The Every Dollar Counts Act, championed by Rep. Greg Murphy, aims to close that loophole by mandating that all out‑of‑pocket drug expenditures—whether sourced from DTP platforms or traditional pharmacies—count toward a patient’s deductible and maximum out‑of‑pocket threshold. By aligning deductible accounting with actual spending, the bill could lower the effective cost of high‑price drugs, encourage broader use of cost‑saving digital channels, and create a more level playing field for pharmacy providers competing on price.

If enacted, the legislation would have ripple effects across the healthcare ecosystem. Insurers may need to redesign benefit structures, while pharmaceutical manufacturers could see increased pressure to lower list prices as competition intensifies. Moreover, the policy could accelerate the digital transformation of drug distribution, prompting more investment in telehealth‑integrated pharmacy services. Stakeholders should monitor the bill’s progress, as its passage could reshape pricing strategies, patient access, and the overall economics of the U.S. pharmaceutical market.